Immune checkpoint inhibitors (ICIs), such as αPD−1/PD-L1 or αCTLA−4 therapy have achieved “breakthrough cancer therapy” status as a result of durable tumor remissions seen in a number of metastatic cancers including melanoma, bladder, and lung cancers. Here, CD274 is linked to neoplasm.